Beruflich Dokumente
Kultur Dokumente
1 Introduction
The company began its journey as Pfizer (Bangladesh) Limited in 1972. It passed two successful
decades as a subsidiary of Pfizer Corporation. In the late 1990s Pfizer had shifted from formulations
to research and in 1993 the company named as Renata. Since its inception it was conceived to
manufacture ethical drugs.
1.3 Mission
Mission statement describes a company's function and fundamentals. The mission of Renata Limited
is:
"To provide maximum value to our customer, shareholders, Colleagues and communities where we
leave and work"
The mission statement articulates the company's purpose both for the organization, for the public as
well.
1.4 Vision
Vision is the ultimate goal of an organization. The vision of Renata is as under:
"To establish Renata Permanency among the best of Innovative branded generic companies.
By using their innovation Renata permanently wants to establish as a one of the best pharmaceuticals
company
2012
Taka
10,034,450,476
8,788,770,209
5,080,969,411
4,646,730,752
Value Added
4,953,481,065
4,142,039,457
Application:
Salaries and benefits paid to Employees
1,067,954,907
21.6
873,039,472
21.1
1,968,031,994
39.7
1,565,223,965
37.8
429,297,480
8.7
370,881,897
9.0
Contribution to WPPF
94,267,953
1.9
85,618,793
2.1
42,887,265
0.9
75,165,779
1.8
Dividend to Shareholders
353,023,430
7.1
240,055,938
5.8
998,018,036
20.1
932,053,613
22.5
4,953,481,065
100.0
4,142,039,457
100.0%
Total
Lenders
Company
Contribution to WPPF
21.6%
21.1%
20.1%
22.5%
7.1%
5.8%
0.9%
1.9%
8.7%
1.8%
2013
2.1%
9.0%
2012
39.7%
37.8%
Figures in Taka
Share
Revaluation
Tax holiday
Retained
Total
capital
surplus
reserve
earnings
225,935,000
158,434,421
56,483,750
(56,483,750)
(135,561,000)
(135,561,000)
157,382
157,382
(635,885)
635,885
- 1,247,275,330
1,247,275,330
75,165,779
(75,165,779)
282,418,750
157,955,917
206,609,359
4,423,495,722
5,070,479,748
282,418,750
157,955,917
206,609,359 4,423,495,722
5,070,479,748
70,604,680
(70,604,680)
(169,451,250)
(169,451,250)
157,382
157,382
(635,885)
635,885
- 1,393,928,731
1,393,928,731
42,887,265
(42,887,265)
353,023,430
157,477,414
249,496,624
5,535,117,143
6,295,114,611
131,443,579 3,442,795,036
3,958,608,036
We have audited the accompanying financial statements of Renata Oncology Limited which comprise the
Statement of Financial Position as at December 31, 2013 and a summary of significant accounting policies
and other explanatory notes.
Notes
Share Capital
Other Payables (Renata Limited)
Amount in Taka
4.0
6.0
80,000,000
73,984,168
Others
11,500
Total
153,995,668
5.0
79,912,400
Capital Work-in-Progress
73,719,168
Deferred Expenses
Cash and Bank Balances
7.0
8.0
276,500
87,600
364,100
Total
153,995,668
Director
Chairman
Chartered Accountants
audit also includes evaluating the appropriateness of accounting policies used and the
reasonableness of accounting estimates made by management, as well as evaluating the overall
presentation of the financial statements.
7. Investment in subsidiaries
Consolidated and Separate Financial Statements as per BAS 27 is to enhance the
relevance, reliability and comparability of the information that a parent entity provides
in its separate financial statements and in its consolidated financial statements for a
group of entities under its control. The information that an entity must disclose to
enable users of the financial statements to evaluate the nature of the relationship
between the entity and its subsidiaries.
2013
No. of
shares
Value
Taka
2012
Value
Taka
419,949
60,570,476
60,570,476
24,999
2,499,900
2,499,900
7,999,900
79,999,000
8,444,848
143,069,376
63,070,376
Opinion
In our opinion, the financial statements prepared in accordance with the Bangladesh Accounting
Standards (BASs) and Bangladesh Financial Reporting Standards (BFRSs), give a true and fair
view of the financial position of Renata Limited as at 31 December 2013 and the results of its
financial performance and its statement of cash flows for the year then ended and comply with
the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and
regulations. In our opinion, the financial statements present fairly, in all material respects, the
financial position of Renata Oncology Limited which comprise the Statement of Financial
Position as at December 31, 2013, and all other related notes for the year then ended in
accordance with Bangladesh Financial Reporting Standards and comply with the Companies Act
1994 and other applicable laws and regulations.
We also report that:
1. Awe have obtained all the information and explanations which to the best of our
knowledge and belief were necessary for the purposes of our audit and made due
verification thereof;
2. in our opinion, proper books of account as required by law have been kept by the
Company so far as it appeared from our examination of those books;
3. the statement of financial position and statement of comprehensive income along with the
annexed notes 1 to 42 dealt with by the report are in agreement with the books of
account; and
The expenditure incurred and payments made were for the purposes of the Company's business.
CONCLUSION
From the total analysis, we can summarize that Renata Ltd. has been doing pretty good
throughout the years. It is true that last year their return did decline but it is still pretty much
satisfactory. Therefore, we can conclude that Square Pharmaceuticals Ltd. is a good enough
company to invest on. The Renata Pharmaceuticals Ltd. financial analysis indicates that it has
been also doing pretty good throughout the years but not as well as the Renata Ltd.
REFERENCES: